StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Scemblix (asciminib by Quarter

Scemblix (asciminib — chronic myeloid leukemia Ph+ CML) ($M)

QuarterlyAnnual

Novartis Scemblix (asciminib: $593M in Q3 2026, up 65.6% from a year earlier. That is the highest of the 20 quarters on record here.

Latest, Q3 2026
593
Period ended Sep 30, 2026
Change on a year earlier
+65.6%
358 in Q3 2025
History
20 quarters
Since Q4 2021
Sources
16
Documents cited below

Where the Q3 2026 figure comes from

“|| Scemblix | 593 | 358 | 66 | 67”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedScemblix (asciminib — chronic myeloid leukemia Ph+ CML) ($M)Year on yearSource
Q3 2026Sep 30, 2026593+65.6%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026562+88.6%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026433+81.9%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025391+88.9%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025358+96.7%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 2025298+81.7%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 2025238+75.0%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 2024207+65.6%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 2024182+71.7%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 2024164+54.7%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 2024136+78.9%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 2023125+140.4%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 2023106+158.5%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 2023106+241.9%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 202376+204.0%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 202252+642.9%Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up scemblix (asciminib

Cite this data

StockData. (2026). Novartis Scemblix (asciminib ($M), quarterly Q4 2021–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-scemblix

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.